Market Report: Taking Stock
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A policy change at a leading private client stockbroker hit some market favourites. The firm decided to restrict T-25 trades, in particular clamping down on long-running roll-overs. Its action prompted forced selling of some of the favourite punting stocks, such as BTG, off 17.5p at 675.5p, Jarvis (11.5p at 337.5p) and Shield Diagnostic (32.5p at 700p).
Shield has results tomorrow. It is suspected it will accompany its figures with developments about the commercialisation of its heart disease detection method and, possibly, that US group Abbot is taking a stake.
Key 2, publishing CD Rom training products, is the latest Ofex hot stock. Placed at 20p three weeks ago, the shares have topped 60p, although they fell 3p to 57.5p yesterday.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments